Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China

This article was originally published in The Pink Sheet Daily

Executive Summary

The deal also signals Merck's partnering strategy in emerging markets for its branded and innovative products, especially in Asia. The company expects EMs to contribute 25% of Merck's global sales by 2013.

You may also be interested in...



Simcere Acquires Manufacturing Rights For Generic Crestor In China; Hopes Sales Force Will Provide Edge Over Competition

SHANGHAI - Chinese firm Simcere signed an agreement with Tianjin Tianda Pharmaceutical to acquire the manufacturing license in China for Tianda's rosuvastatin, a generic version of AstraZeneca's cholesterol and atherosclerosis treatment Crestor (rosuvastatin), Simcere announced Nov. 9

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa

With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.

Topics

UsernamePublicRestriction

Register

PS072554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel